

Kenneth G Saag

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/569405/publications.pdf>

Version: 2024-02-01

298
papers

29,806
citations

8755

75
h-index

5255

165
g-index

305
all docs

305
docs citations

305
times ranked

23119
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids. <i>Arthritis and Rheumatology</i> , 2022, 74, 604-611. | 5.6 | 6 |
| 2 | Whatâ€™s new on the front-line of gout pharmacotherapy?. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 453-464. | 1.8 | 5 |
| 3 | COVIDâ€™19 vaccine uptake and vaccine hesitancy in rheumatic disease patients receiving immunomodulatory therapies in community practice settings. <i>Arthritis and Rheumatology</i> , 2022, 74, 1091-1092. | 5.6 | 9 |
| 4 | Osteoporosis in 10 years time: a glimpse into the future of osteoporosis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210835. | 2.7 | 30 |
| 5 | The clinicianâ€™s guide to prevention and treatment of osteoporosis. <i>Osteoporosis International</i> , 2022, 33, 2049-2102. | 3.1 | 255 |
| 6 | Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial. <i>Arthritis and Rheumatology</i> , 2022, 74, 1593-1601. | 5.6 | 10 |
| 7 | Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region. <i>Journal of Clinical Densitometry</i> , 2021, 24, 3-13. | 1.2 | 35 |
| 8 | SARS CoV-2 infection among patients using immunomodulatory therapies. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 269-271. | 0.9 | 29 |
| 9 | Which factors predict discordance between a patient and physician on a gout flare?. <i>Rheumatology</i> , 2021, 60, 773-779. | 1.9 | 5 |
| 10 | Dataâ€™Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Womenâ€™s Rheumatoid Arthritis Sequential Study Registry. <i>Arthritis Care and Research</i> , 2021, 73, 471-480. | 3.4 | 12 |
| 11 | Real-world bone turnover marker use: impact on treatment decisions and fracture. <i>Osteoporosis International</i> , 2021, 32, 831-840. | 3.1 | 13 |
| 12 | Glucocorticoid-induced osteoporosis and Cushingâ€™s syndrome. , 2021, , 1103-1138. | | 0 |
| 13 | The Contribution of Patient, Primary Care Physician, and Primary Care Clinic Factors to Good Bone Health Care. , 2021, 25, 1-3. | | 1 |
| 14 | Machine learning approaches for the prediction of bone mineral density by using genomic and phenotypic data of 5130 older men. <i>Scientific Reports</i> , 2021, 11, 4482. | 3.3 | 6 |
| 15 | Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis. <i>Osteoporosis International</i> , 2021, 32, 1879-1888. | 3.1 | 3 |
| 16 | Higher Serum Urate Levels Are Associated With an Increased Risk for Sudden Cardiac Death. <i>Journal of Rheumatology</i> , 2021, 48, 1745-1753. | 2.0 | 3 |
| 17 | Disruptions in Rheumatology Care and the Rise of Telehealth in Response to the COVIDâ€™19 Pandemic in a Community Practiceâ€™Based Network. <i>Arthritis Care and Research</i> , 2021, 73, 1153-1161. | 3.4 | 32 |
| 18 | A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares. <i>Arthritis and Rheumatology</i> , 2021, 73, 1533-1542. | 5.6 | 45 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Variation in serum urate levels in the absence of gout and urate lowering therapy. BMC Rheumatology, 2021, 5, 32. | 1.6 | 2 |
| 20 | Denosumab did not improve computerized tomography erosion scores when added to intensive urate-lowering therapy in gout: Results from a pilot randomized controlled trial. Seminars in Arthritis and Rheumatism, 2021, 51, 1218-1223. | 3.4 | 2 |
| 21 | Serum urate as a proposed surrogate outcome measure in gout trials: From the OMERACT working group. Seminars in Arthritis and Rheumatism, 2021, 51, 1378-1385. | 3.4 | 3 |
| 22 | Simulation-based power and sample size calculation for designing interrupted time series analyses of count outcomes in evaluation of health policy interventions. Contemporary Clinical Trials Communications, 2020, 17, 100474. | 1.1 | 20 |
| 23 | Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. Journal of Bone and Mineral Research, 2020, 35, 36-52. | 2.8 | 146 |
| 24 | Design, analysis, power, and sample size calculation for three-phase interrupted time series analysis in evaluation of health policy interventions. Journal of Evaluation in Clinical Practice, 2020, 26, 826-841. | 1.8 | 6 |
| 25 | Burosumab in tumor-induced osteomalacia: A case report. Joint Bone Spine, 2020, 87, 81-83. | 1.6 | 21 |
| 26 | Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort. Journal of Rheumatology, 2020, 47, 449-460. | 2.0 | 11 |
| 27 | Temporal Trends and Factors Associated with Bisphosphonate Discontinuation and Restart. Journal of Bone and Mineral Research, 2020, 35, 478-487. | 2.8 | 13 |
| 28 | Severity of Hypertension Mediates the Association of Hyperuricemia With Stroke in the REGARDS Case Cohort Study. Hypertension, 2020, 75, 246-256. | 2.7 | 37 |
| 29 | Comorbidities in gout and hyperuricemia: causality or epiphenomena?. Current Opinion in Rheumatology, 2020, 32, 126-133. | 4.3 | 23 |
| 30 | A Randomized Internet-Based Pilot Feasibility and Planning Study of Cherry Extract and Diet Modification in Gout. Journal of Clinical Rheumatology, 2020, 26, 147-156. | 0.9 | 9 |
| 31 | Allopurinol adherence and its predictors in gout: a national cohort study in US veterans. Lancet Rheumatology, The, 2020, 2, e281-e291. | 3.9 | 7 |
| 32 | Cardiovascular safety risks associated with gout treatments. Expert Opinion on Drug Safety, 2020, 19, 1143-1154. | 2.4 | 2 |
| 33 | Physical activity measured using wearable activity tracking devices associated with gout flares. Arthritis Research and Therapy, 2020, 22, 181. | 3.5 | 15 |
| 34 | Use of path modeling to inform a clinical decision support application to encourage osteoporosis medication use. Research in Social and Administrative Pharmacy, 2020, 17, 1267-1275. | 3.0 | 0 |
| 35 | Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. Journal of Orthopaedic Trauma, 2020, 34, e125-e141. | 1.4 | 10 |
| 36 | Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture. Clinical Therapeutics, 2020, 42, 1099-1107.e1. | 2.5 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1784-1802. | 2.0 | 14 |
| 38 | Imminent Fracture Risk: A Call to Action for Rheumatologists. <i>Arthritis Care and Research</i> , 2020, 72, 741-743. | 3.4 | 4 |
| 39 | Osteoporosis screening using computed tomography for men with prostate cancer: results of a prospective study. <i>Archives of Osteoporosis</i> , 2020, 15, 32. | 2.4 | 3 |
| 40 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699. | 0.9 | 1,860 |
| 41 | A REDCap-based model for electronic consent (eConsent): Moving toward a more personalized consent. <i>Journal of Clinical and Translational Science</i> , 2020, 4, 345-353. | 0.6 | 65 |
| 42 | Racial Disparities Exist in Outcomes After Major Fragility Fractures. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1803-1810. | 2.6 | 22 |
| 43 | Reply to Serious Adverse Events With Romosozumab Use in Japanese Patients: Need for Clear Formulation of Contraindications Worldwide. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 996-997. | 2.8 | 3 |
| 44 | Gout is associated with an increased risk for incident heart failure among older adults: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort study. <i>Arthritis Research and Therapy</i> , 2020, 22, 86. | 3.5 | 21 |
| 45 | Factors associated with the contemplative stage of readiness to initiate osteoporosis treatment. <i>Osteoporosis International</i> , 2020, 31, 1283-1290. | 3.1 | 6 |
| 46 | Identification of Gout Flares in Chief Complaint Text Using Natural Language Processing. <i>AMIA ... Annual Symposium proceedings</i> , 2020, 2020, 973-982. | 0.2 | 0 |
| 47 | Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 1136-1146. | 2.8 | 6 |
| 48 | Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 143-153. | 5.6 | 16 |
| 49 | Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. <i>Rheumatology</i> , 2019, 58, 61-69. | 1.9 | 17 |
| 50 | Comparison of an interactive voice response system and smartphone application in the identification of gout flares. <i>Arthritis Research and Therapy</i> , 2019, 21, 160. | 3.5 | 4 |
| 51 | Vascular Consequences of Hyperuricemia and Hypouricemia. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 453-464. | 1.9 | 8 |
| 52 | <p>Anabolics in the management of glucocorticoid-induced osteoporosis: an evidence-based review of long-term safety, efficacy and place in therapy</p>. <i>Core Evidence</i> , 2019, Volume 14, 41-50. | 4.7 | 17 |
| 53 | Balancing benefits and risks in the era of biologics. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2019, 11, 1759720X1988397. | 2.7 | 10 |
| 54 | Association of Early Postoperative Pain Trajectories With Longer-term Pain Outcome After Primary Total Knee Arthroplasty. <i>JAMA Network Open</i> , 2019, 2, e1915105. | 5.9 | 30 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Characteristics of older adults using patient web portals to view their DXA results. BMC Medical Informatics and Decision Making, 2019, 19, 187. | 3.0 | 3 |
| 56 | Glucocorticoid-induced osteoporosis: from clinical trials to clinical practice. Therapeutic Advances in Musculoskeletal Disease, 2019, 11, 1759720X1987646. | 2.7 | 18 |
| 57 | Reply. Arthritis and Rheumatology, 2019, 71, 1771-1772. | 5.6 | 0 |
| 58 | Osteoporosis Pathophysiology, Epidemiology, and Screening in Rheumatoid Arthritis. Current Rheumatology Reports, 2019, 21, 34. | 4.7 | 85 |
| 59 | Tools and Methods for Real-World Evidence Generation. Rheumatic Disease Clinics of North America, 2019, 45, 275-289. | 1.9 | 9 |
| 60 | A Qualitative Study of the Postoperative Pain Management Educational Needs of Total Joint Replacement Patients. Pain Management Nursing, 2019, 20, 345-351. | 0.9 | 11 |
| 61 | Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women. Bone, 2019, 123, 191-195. | 2.9 | 26 |
| 62 | Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporosis International, 2019, 30, 1145-1156. | 3.1 | 120 |
| 63 | Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial. Arthritis and Rheumatology, 2019, 71, 1174-1184. | 5.6 | 102 |
| 64 | Race Plays a Role in the Knowledge, Attitudes, and Beliefs of Women with Osteoporosis. Journal of Racial and Ethnic Health Disparities, 2019, 6, 707-718. | 3.2 | 10 |
| 65 | FRIO469...CHANGES IN DKK-1, SCLEROSTIN, AND RANKL SERUM LEVELS FOLLOWING DISCONTINUATION OF LONG-TERM DENOSUMAB TREATMENT IN POSTMENOPAUSAL WOMEN. , 2019, , . | | 0 |
| 66 | Pragmatic Clinical Trials in Osteoporosis. Current Osteoporosis Reports, 2019, 17, 521-526. | 3.6 | 2 |
| 67 | Glucocorticoid-induced osteoporosis update. Current Opinion in Rheumatology, 2019, 31, 388-393. | 4.3 | 55 |
| 68 | Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts™ consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. Osteoporosis International, 2019, 30, 45-57. | 3.1 | 67 |
| 69 | Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial. American Journal of Medicine, 2019, 132, 354-361. | 1.5 | 49 |
| 70 | Sex differences in osteoporosis self-efficacy among community-residing older adults presenting for DXA. Osteoporosis International, 2019, 30, 1033-1041. | 3.1 | 4 |
| 71 | SAT-519 Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture Representative of Covered Commercial Insurance Enrollees. Journal of the Endocrine Society, 2019, 3, . | 0.2 | 0 |
| 72 | Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes and Endocrinology,the, 2018, 6, 445-454. | 11.4 | 148 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Is Rheumatoid Arthritis a Cardiovascular Riskâ€Equivalent to Diabetes Mellitus?. Arthritis Care and Research, 2018, 70, 1694-1699. | 3.4 | 14 |
| 74 | Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors. Annals of the Rheumatic Diseases, 2018, 77, 1012-1016. | 0.9 | 48 |
| 75 | Evaluation of a Multimodal, Direct-to-Patient Educational Intervention Targeting Barriers to Osteoporosis Care: A Randomized Clinical Trial. Journal of Bone and Mineral Research, 2018, 33, 763-772. | 2.8 | 27 |
| 76 | Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population-based study. Annals of the Rheumatic Diseases, 2018, 77, 386-392. | 0.9 | 23 |
| 77 | Hip fracture trends in the United States, 2002 to 2015. Osteoporosis International, 2018, 29, 717-722. | 3.1 | 198 |
| 78 | Just the FRAX: Management of Glucocorticoid-Induced Osteoporosis. Gastroenterology, 2018, 154, 748-750. | 1.3 | 3 |
| 79 | Diet and exercise changes following bone densitometry in the Patient Activation After DXA Result Notification (PAADRN) study. Archives of Osteoporosis, 2018, 13, 4. | 2.4 | 4 |
| 80 | Taking an Interdisciplinary Approach to Understanding and Improving Medication Adherence. Journal of General Internal Medicine, 2018, 33, 136-138. | 2.6 | 5 |
| 81 | Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis. New England Journal of Medicine, 2018, 378, 194-196. | 27.0 | 21 |
| 82 | How to use bisphosphonates safely and optimally. Rheumatology, 2018, 57, 1875-1876. | 1.9 | 4 |
| 83 | Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. New England Journal of Medicine, 2018, 378, 1200-1210. | 27.0 | 601 |
| 84 | Brief Report: Validation of a Definition of Flare in Patients With Established Gout. Arthritis and Rheumatology, 2018, 70, 462-467. | 5.6 | 68 |
| 85 | The prevalence of overtreatment of osteoporosis: results from the PAADRN trial. Archives of Osteoporosis, 2018, 13, 103. | 2.4 | 2 |
| 86 | Importance of Recent Fracture as Predictor of Imminent Fracture Risk. Current Osteoporosis Reports, 2018, 16, 738-745. | 3.6 | 22 |
| 87 | Healthcare Providersâ€™ Recommendations for Physical Activity among US Arthritis Population: A Cross-Sectional Analysis by Race/Ethnicity. Arthritis, 2018, 2018, 1-9. | 2.0 | 6 |
| 88 | Glucocorticoid-Induced Osteoporosis: Update on Management. Current Treatment Options in Rheumatology, 2018, 4, 279-287. | 1.4 | 1 |
| 89 | ACTIVEExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2949-2957. | 3.6 | 131 |
| 90 | Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study. Arthritis Research and Therapy, 2018, 20, 99. | 3.5 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 91 | Improving drug adherence in osteoporosis: an update on more recent studies. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2018, 10, 141-149. | 2.7 | 28 |
| 92 | A Performing Arts Intervention Improves Cognitive Dysfunction in 50 Hospitalized Older Adults. <i>Innovation in Aging</i> , 2018, 2, igy013. | 0.1 | 4 |
| 93 | Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected Conditions. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1881-1888. | 2.8 | 47 |
| 94 | Moving Career Development Upstream: Evaluation of a Course for Internal Medicine Trainees Contemplating Career Pathways in Academic Medicine. <i>Southern Medical Journal</i> , 2018, 111, 471-475. | 0.7 | 3 |
| 95 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977. | 0.9 | 3,366 |
| 96 | The cost of a patient activation intervention for achieving successful outcomes: results from the PAADRN randomized controlled trial. <i>Osteoporosis International</i> , 2017, 28, 3061-3066. | 3.1 | 0 |
| 97 | Racial Differences and Disparities in Osteoporosis-related Bone Health. <i>Medical Care</i> , 2017, 55, 561-568. | 2.4 | 11 |
| 98 | The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the USA. <i>Osteoporosis International</i> , 2017, 28, 1225-1232. | 3.1 | 92 |
| 99 | The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the United States: supplementary presentation. <i>Osteoporosis International</i> , 2017, 28, 3283-3284. | 3.1 | 14 |
| 100 | Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study. <i>Rheumatology</i> , 2017, 56, 2170-2178. | 1.9 | 90 |
| 101 | Self-perception of fracture risk: what can it tell us?. <i>Osteoporosis International</i> , 2017, 28, 3495-3500. | 3.1 | 9 |
| 102 | Editorial: Response to the American College of Physicians Osteoporosis Guideline, 2017 Update. <i>Arthritis and Rheumatology</i> , 2017, 69, 2097-2101. | 5.6 | 6 |
| 103 | Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. <i>New England Journal of Medicine</i> , 2017, 377, 1417-1427. | 27.0 | 901 |
| 104 | Validity, reliability, and responsiveness to change of the "Osteoporosis and You" knowledge scale. <i>Osteoporosis International</i> , 2017, 28, 3379-3388. | 3.1 | 0 |
| 105 | Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). <i>Nature Reviews Rheumatology</i> , 2017, 13, 561-568. | 8.0 | 74 |
| 106 | Patient-reported reasons for nonadherence to recommended osteoporosis pharmacotherapy. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2017, 57, 503-509. | 1.5 | 18 |
| 107 | Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study. <i>Osteoporosis International</i> , 2017, 28, 2495-2503. | 3.1 | 5 |
| 108 | Lesinurad Combined With Allopurinol: A Randomized, Double-blind, Placebo-controlled Study in Gout Patients With an Inadequate Response to Standard-of-care Allopurinol (a US-based Study). <i>Arthritis and Rheumatology</i> , 2017, 69, 203-212. | 5.6 | 154 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Activating Patients With a Tailored Bone Density Test Results Letter and Educational Brochure: the PAADRN Randomized Controlled Trial. <i>Journal of Clinical Densitometry</i> , 2017, 20, 464-471. | 1.2 | 7 |
| 110 | Evaluation of a "Just-in-Time" Nurse Consultation on Bone Health: A Pilot Randomized Controlled Trial. , 2017, 21, 16-112. | | 3 |
| 111 | Understanding Preferences for Osteoporosis Information to Develop an Osteoporosis Patient Education Brochure. , 2017, 21, 16-024. | | 38 |
| 112 | The effects of a patient activation intervention on smoking and excessive drinking cessations: results from the PAADRN randomized controlled trial. <i>Osteoporosis International</i> , 2017, 28, 3055-3060. | 3.1 | 0 |
| 113 | Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment. <i>Arthritis and Rheumatology</i> , 2016, 68, 2035-2043. | 5.6 | 95 |
| 114 | Increase in Fracture Risk Following Unintentional Weight Loss in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1466-1472. | 2.8 | 29 |
| 115 | Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide. <i>Arthritis and Rheumatology</i> , 2016, 68, 2122-2128. | 5.6 | 76 |
| 116 | Analysis of health care claims during the peri-transfer stage of transition from pediatric to adult care among juvenile idiopathic arthritis patients. <i>Pediatric Rheumatology</i> , 2016, 14, 49. | 2.1 | 12 |
| 117 | Socio-demographic differences in risk information seeking sources for non-steroidal anti-inflammatory drugs (NSAIDs). <i>International Journal of Medical Informatics</i> , 2016, 94, 222-227. | 3.3 | 1 |
| 118 | Understanding practice-based research participation: The differing motivations of engaged vs. non-engaged clinicians in pragmatic clinical trials. <i>Contemporary Clinical Trials Communications</i> , 2016, 4, 136-140. | 1.1 | 21 |
| 119 | 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1-26. | 5.6 | 1,880 |
| 120 | A multi-modal intervention for Activating Patients at Risk for Osteoporosis (APROPOS): Rationale, design, and uptake of online study intervention material. <i>Contemporary Clinical Trials Communications</i> , 2016, 4, 14-24. | 1.1 | 13 |
| 121 | The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale. <i>Contemporary Clinical Trials</i> , 2016, 50, 238-244. | 1.8 | 5 |
| 122 | Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAMP-UP) Study. <i>Contemporary Clinical Trials</i> , 2016, 50, 106-115. | 1.8 | 12 |
| 123 | Evaluating the effectiveness of a patient storytelling DVD intervention to encourage physician-patient communication about nonsteroidal anti-inflammatory drug (NSAID) use. <i>Patient Education and Counseling</i> , 2016, 99, 1837-1844. | 2.2 | 6 |
| 124 | Patient-activation and guideline-concordant pharmacological treatment after bone density testing: the PAADRN randomized controlled trial. <i>Osteoporosis International</i> , 2016, 27, 3513-3524. | 3.1 | 22 |
| 125 | Effects of a DXA result letter on satisfaction, quality of life, and osteoporosis knowledge: a randomized controlled trial. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 369. | 1.9 | 11 |
| 126 | The National Osteoporosis Foundation's methods and processes for developing position statements. <i>Archives of Osteoporosis</i> , 2016, 11, 22. | 2.4 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1813-1818. | 0.9 | 90 |
| 128 | Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Aging Clinical and Experimental Research</i> , 2016, 28, 1-16. | 2.9 | 22 |
| 129 | A pragmatic randomized trial comparing tablet computer informed consent to traditional paper-based methods for an osteoporosis study. <i>Contemporary Clinical Trials Communications</i> , 2016, 3, 32-38. | 1.1 | 32 |
| 130 | Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare. <i>Arthritis and Rheumatology</i> , 2016, 68, 56-66. | 5.6 | 136 |
| 131 | Glucocorticoid-induced Osteoporosis. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, 177-189. | 1.9 | 93 |
| 132 | 2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2015, 67, 2557-2568. | 5.6 | 393 |
| 133 | The Safety of Low-Dose Glucocorticoids in Rheumatic Diseases: Results from Observational Studies. <i>NeuroImmunoModulation</i> , 2015, 22, 72-82. | 1.8 | 9 |
| 134 | Bisphosphonates and glucocorticoid-induced osteoporosis: cons. <i>Endocrine</i> , 2015, 49, 628-634. | 2.3 | 20 |
| 135 | Risk of Hospitalized Infection Among Rheumatoid Arthritis Patients Concurrently Treated With a Biologic Agent and Denosumab. <i>Arthritis and Rheumatology</i> , 2015, 67, 1456-1464. | 5.6 | 51 |
| 136 | An Internet-based Controlled Trial Aimed to Improve Osteoporosis Prevention among Chronic Glucocorticoid Users. <i>Journal of Rheumatology</i> , 2015, 42, 1478-1483. | 2.0 | 7 |
| 137 | Evaluating and mitigating fracture risk in established rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 614-627. | 3.3 | 18 |
| 138 | Modifiable Factors Associated with Allopurinol Adherence and Outcomes Among Patients with Gout in an Integrated Healthcare System. <i>Journal of Rheumatology</i> , 2015, 42, 504-512. | 2.0 | 69 |
| 139 | Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1065-1071. | 0.9 | 79 |
| 140 | Systemic glucocorticoids in rheumatology. , 2015, , 423-433. | | 5 |
| 141 | The Validity of Claims-Based Algorithms to Identify Serious Hypersensitivity Reactions and Osteonecrosis of the Jaw. <i>PLoS ONE</i> , 2015, 10, e0131601. | 2.5 | 6 |
| 142 | Fractures and mortality in relation to different osteoporosis treatments. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 302-9. | 0.8 | 7 |
| 143 | Developing a bone mineral density test result letter to send to patients: a mixed-methods study. <i>Patient Preference and Adherence</i> , 2014, 8, 827. | 1.8 | 13 |
| 144 | Improving bone mineral density reporting to patients with an illustration of personal fracture risk. <i>BMC Medical Informatics and Decision Making</i> , 2014, 14, 101. | 3.0 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | OMERACT Endorsement of Measures of Outcome for Studies of Acute Gout. <i>Journal of Rheumatology</i> , 2014, 41, 569-573. | 2.0 | 26 |
| 146 | Risk of Hospitalized Bacterial Infections Associated With Biologic Treatment Among US Veterans With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 990-997. | 3.4 | 90 |
| 147 | Effect of Self-referral on Bone Mineral Density Testing and Osteoporosis Treatment. <i>Medical Care</i> , 2014, 52, 743-750. | 2.4 | 18 |
| 148 | Death, Debility, and Destitution Following Hip Fracture. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2014, 69A, 346-353. | 3.6 | 125 |
| 149 | Use of health plan combined with registry data to predict clinical trial recruitment. <i>Clinical Trials</i> , 2014, 11, 96-101. | 1.6 | 7 |
| 150 | Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study. <i>Osteoporosis International</i> , 2014, 25, 85-95. | 3.1 | 66 |
| 151 | Use of pharmacologic agents for the primary prevention of osteoporosis among older women with low bone mass. <i>Osteoporosis International</i> , 2014, 25, 317-324. | 3.1 | 7 |
| 152 | Bone safety of low-dose glucocorticoids in rheumatic diseases. <i>Annals of the New York Academy of Sciences</i> , 2014, 1318, 55-64. | 3.8 | 13 |
| 153 | The Recent Prevalence of Osteoporosis and Low Bone Mass in the United States Based on Bone Mineral Density at the Femoral Neck or Lumbar Spine. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 2520-2526. | 2.8 | 1,305 |
| 154 | Fracture mortality: associations with epidemiology and osteoporosis treatment. <i>Nature Reviews Endocrinology</i> , 2014, 10, 592-602. | 9.6 | 140 |
| 155 | Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAFETY Assessment of Biologic ThERapy (SABER) Study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1942-1948. | 0.9 | 100 |
| 156 | Multimodal intervention to improve osteoporosis care in home health settings: results from a cluster randomized trial. <i>Osteoporosis International</i> , 2013, 24, 2555-2560. | 3.1 | 5 |
| 157 | Glucocorticoid-Induced Osteoporosis. , 2013, , 1191-1223. | | 5 |
| 158 | Osteopenia: Debates and Dilemmas. <i>Current Rheumatology Reports</i> , 2013, 15, 384. | 4.7 | 19 |
| 159 | Prevention and Treatment of Bone Changes Associated with Exposure to Glucocorticoids. <i>Current Osteoporosis Reports</i> , 2013, 11, 341-347. | 3.6 | 11 |
| 160 | The PAADRN Study: A design for a randomized controlled practical clinical trial to improve bone health. <i>Contemporary Clinical Trials</i> , 2013, 34, 90-100. | 1.8 | 24 |
| 161 | Physicians' explanations for apparent gaps in the quality of rheumatology care: Results from the US Medicare Physician Quality Reporting System. <i>Arthritis Care and Research</i> , 2013, 65, 235-243. | 3.4 | 21 |
| 162 | FRI0529...Comparative risks for serious infections associated with biologics in high risk rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A553.3-A554. | 0.9 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Study design considerations for a large simple trial of bisphosphonates. <i>Current Opinion in Rheumatology</i> , 2013, 25, 517-523. | 4.3 | 3 |
| 164 | Challenges in Defining Quality of Care for Glucocorticoid-induced Osteoporosis: Defending Good Against Perfect. <i>Journal of Rheumatology</i> , 2013, 40, 1640-1642. | 2.0 | 3 |
| 165 | Choosing wisely: The American College of Rheumatology's top 5 list of things physicians and patients should question. <i>Arthritis Care and Research</i> , 2013, 65, 329-339. | 3.4 | 89 |
| 166 | Tumor Necrosis Factor, Tuberculosis, Testing, and Treatment: Teeing Up the Questions. <i>Arthritis Care and Research</i> , 2013, 65, 1719-1721. | 3.4 | 1 |
| 167 | When, Where and How Osteoporosis-Associated Fractures Occur: An Analysis from the Global Longitudinal Study of Osteoporosis in Women (GLOW). <i>PLoS ONE</i> , 2013, 8, e83306. | 2.5 | 63 |
| 168 | Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 924-928. | 0.9 | 63 |
| 169 | A randomized trial of a mailed intervention and self-scheduling to improve osteoporosis screening in postmenopausal women. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 2603-2610. | 2.8 | 14 |
| 170 | The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. <i>Osteoporosis International</i> , 2012, 23, 2141-2150. | 3.1 | 112 |
| 171 | Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States. <i>Contemporary Clinical Trials</i> , 2012, 33, 1211-1216. | 1.8 | 23 |
| 172 | Drug Treatment of Hyperuricemia to Prevent Cardiovascular Outcomes. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 1-6. | 2.2 | 9 |
| 173 | Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. <i>Bone</i> , 2012, 50, 289-295. | 2.9 | 55 |
| 174 | Improving osteoporosis care in high-risk home health patients through a high-intensity intervention. <i>Contemporary Clinical Trials</i> , 2012, 33, 206-212. | 1.8 | 8 |
| 175 | Riloncept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: Results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. <i>Arthritis Care and Research</i> , 2012, 64, 1462-1470. | 3.4 | 94 |
| 176 | Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. <i>Arthritis Care and Research</i> , 2012, 64, 1480-1489. | 3.4 | 49 |
| 177 | From Fracture Risk Prediction to Evaluating Fracture Patterns: Recent Advances in the Epidemiology of Osteoporosis. <i>Current Rheumatology Reports</i> , 2012, 14, 205-211. | 4.7 | 8 |
| 178 | Short-term and long-term safety of glucocorticoids in rheumatoid arthritis. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2012, 70 Suppl 1, 21-5. | 0.7 | 6 |
| 179 | Long-term Safety Concerns of Antiresorptive Therapy. <i>Rheumatic Disease Clinics of North America</i> , 2011, 37, 387-400. | 1.9 | 17 |
| 180 | Official Positions for FRAX® Clinical Regarding Glucocorticoids: The Impact of the Use of Glucocorticoids on the Estimate by FRAX® of the 10 Year Risk of Fracture. <i>Journal of Clinical Densitometry</i> , 2011, 14, 212-219. | 1.2 | 85 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Obesity Is Not Protective against Fracture in Postmenopausal Women: GLOW. American Journal of Medicine, 2011, 124, 1043-1050. | 1.5 | 446 |
| 182 | Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone, 2011, 49, 493-498. | 2.9 | 78 |
| 183 | An observational study of glucocorticoid-induced osteoporosis prophylaxis in a national cohort of male veterans with rheumatoid arthritis. Osteoporosis International, 2011, 22, 305-315. | 3.1 | 17 |
| 184 | Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW). Osteoporosis International, 2011, 22, 27-35. | 3.1 | 79 |
| 185 | Clinical and demographic factors associated with fractures among older Americans. Osteoporosis International, 2011, 22, 1263-1274. | 3.1 | 73 |
| 186 | Systems-based approaches to osteoporosis and fracture care: policy and research recommendations from the workgroups. Osteoporosis International, 2011, 22, 495-500. | 3.1 | 9 |
| 187 | Is Two Better Than One? Combining Antiresorptive and Anabolic Osteoporosis Medications. Current Osteoporosis Reports, 2011, 9, 109-111. | 3.6 | 0 |
| 188 | Defining quality of care in rheumatology: The American College of Rheumatology white paper on quality measurement. Arthritis Care and Research, 2011, 63, 2-9. | 3.4 | 37 |
| 189 | Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?. Arthritis and Rheumatism, 2011, 63, 325-328. | 6.7 | 47 |
| 190 | Initiation of Tumor Necrosis Factor-Î± Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases. JAMA - Journal of the American Medical Association, 2011, 306, 2331-9. | 7.4 | 305 |
| 191 | The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Annals of the Rheumatic Diseases, 2011, 70, 1401-1406. | 0.9 | 98 |
| 192 | Systemic glucocorticoids in rheumatology. , 2011, , 495-503.e3. | | 1 |
| 193 | Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout. Core Evidence, 2010, 4, 25. | 4.7 | 11 |
| 194 | Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis. Osteoporosis International, 2010, 21, 1573-1584. | 3.1 | 18 |
| 195 | Health Literacy and Happiness: A Community-based Study. Social Indicators Research, 2010, 95, 325-338. | 2.7 | 29 |
| 196 | Identifying types of nursing facility stays using medicare claims data: an algorithm and validation. Health Services and Outcomes Research Methodology, 2010, 10, 100-110. | 1.8 | 62 |
| 197 | American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care and Research, 2010, 62, 1515-1526. | 3.4 | 633 |
| 198 | The Role of Health Literacy and Written Medicine Information in Nonsteroidal Antiinflammatory Drug Risk Awareness. Annals of Pharmacotherapy, 2010, 44, 274-284. | 1.9 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Serum urate and its relationship with alcoholic beverage intake in men and women: findings from the Coronary Artery Risk Development in Young Adults (CARDIA) cohort. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1965-1970. | 0.9 | 63 |
| 200 | Is Withholding Osteoporosis Medication After Fracture Sometimes Rational? A Comparison of the Risk for Second Fracture Versus Death. <i>Journal of the American Medical Directors Association</i> , 2010, 11, 584-591. | 2.5 | 57 |
| 201 | Osteoporosis Care in the United States After Declines in Reimbursements for DXA. <i>Journal of Clinical Densitometry</i> , 2010, 13, 352-360. | 1.2 | 40 |
| 202 | Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. <i>Bone</i> , 2010, 46, 929-934. | 2.9 | 31 |
| 203 | From bone biology to clinical outcome: state of the art and future perspectives. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1415-1419. | 0.9 | 76 |
| 204 | The delivery of evidence-based preventive care for older Americans with arthritis. <i>Arthritis Research and Therapy</i> , 2010, 12, R144. | 3.5 | 43 |
| 205 | Management of Osteoporosis Among Home Health and Long-Term Care Patients with a Prior Fracture. <i>Southern Medical Journal</i> , 2009, 102, 397-404. | 0.7 | 11 |
| 206 | Once-Weekly Oral Alendronate 70 mg in Patients with Glucocorticoid-Induced Bone Loss: A 12-Month Randomized, Placebo-Controlled Clinical Trial. <i>Journal of Rheumatology</i> , 2009, 36, 1705-1714. | 2.0 | 87 |
| 207 | Glucocorticoids and the risk of osteoporosis. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 33-47. | 2.4 | 40 |
| 208 | Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial. <i>Arthritis and Rheumatism</i> , 2009, 60, 3346-3355. | 6.7 | 406 |
| 209 | Quality health care gaps in osteoporosis: How can patients, providers, and the health system do a better job?. <i>Current Osteoporosis Reports</i> , 2009, 7, 27-34. | 3.6 | 22 |
| 210 | Population-Based Fracture Risk Assessment and Osteoporosis Treatment Disparities by Race and Gender. <i>Journal of General Internal Medicine</i> , 2009, 24, 956-962. | 2.6 | 101 |
| 211 | Vertebroplasty and kyphoplasty are associated with an increased risk of secondary vertebral compression fractures: a population-based cohort study. <i>Osteoporosis International</i> , 2009, 20, 819-826. | 3.1 | 104 |
| 212 | Risedronate and Alendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction. <i>Osteoporosis International</i> , 2009, 20, 973-978. | 3.1 | 35 |
| 213 | Estimated prevalence and patterns of presumed osteoporosis among older Americans based on Medicare data. <i>Osteoporosis International</i> , 2009, 20, 1507-1515. | 3.1 | 67 |
| 214 | Do physicians within the same practice setting manage osteoporosis patients similarly? Implications for implementation research. <i>Osteoporosis International</i> , 2009, 20, 1921-1927. | 3.1 | 8 |
| 215 | The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. <i>Osteoporosis International</i> , 2009, 20, 1107-1116. | 3.1 | 79 |
| 216 | Bridging the Osteoporosis Quality Chasm. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 3-7. | 2.8 | 30 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 217 | Health Care Expenditures Associated With Skeletal Fractures Among Medicare Beneficiaries, 1999–2005. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 2050-2055. | 2.8 | 79 |
| 218 | Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 321-327.e7. | 5.0 | 72 |
| 219 | Progress in osteoporosis and fracture prevention: focus on postmenopausal women. <i>Arthritis Research and Therapy</i> , 2009, 11, 251. | 3.5 | 38 |
| 220 | Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?. <i>Arthritis Research and Therapy</i> , 2009, 11, 240. | 3.5 | 52 |
| 221 | Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. <i>Lancet</i> , The, 2009, 373, 1253-1263. | 13.7 | 452 |
| 222 | Improving the Prediction of Medication Compliance. <i>Medical Care</i> , 2009, 47, 334-341. | 2.4 | 87 |
| 223 | Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. <i>Osteoporosis International</i> , 2008, 19, 1613-20. | 3.1 | 121 |
| 224 | Improving quality of care in osteoporosis: Opportunities and challenges. <i>Current Rheumatology Reports</i> , 2008, 10, 123-130. | 4.7 | 12 |
| 225 | Longitudinal Trends in Use of Bone Mass Measurement Among Older Americans, 1999–2005. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1061-1067. | 2.8 | 115 |
| 226 | Benefit of Adherence With Bisphosphonates Depends on Age and Fracture Type: Results From an Analysis of 101,038 New Bisphosphonate Users. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1435-1441. | 2.8 | 100 |
| 227 | Regional Variation in the Denial of Reimbursement for Bone Mineral Density Testing Among US Medicare Beneficiaries. <i>Journal of Clinical Densitometry</i> , 2008, 11, 568-574. | 1.2 | 8 |
| 228 | Drug Insight: choosing a drug treatment strategy for women with osteoporosis—an evidence-based clinical perspective. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 240-248. | 3.2 | 29 |
| 229 | Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3785-3793. | 3.6 | 205 |
| 230 | The epidemiology of glucocorticoid-associated adverse events. <i>Current Opinion in Rheumatology</i> , 2008, 20, 131-137. | 4.3 | 329 |
| 231 | Association of infections and tuberculosis with antitumor necrosis factor alpha therapy. <i>Current Opinion in Rheumatology</i> , 2008, 20, 320-326. | 4.3 | 23 |
| 232 | Glucocorticoid-Induced Osteoporosis. , 2008, , 1135-1166. | | 9 |
| 233 | Challenges in Improving the Quality of Osteoporosis Care for Long-term Glucocorticoid Users. <i>Archives of Internal Medicine</i> , 2007, 167, 591. | 3.8 | 78 |
| 234 | Randomized Trial to Improve Fracture Prevention in Nursing Home Residents. <i>American Journal of Medicine</i> , 2007, 120, 886-892. | 1.5 | 56 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 235 | EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1560-1567. | 0.9 | 325 |
| 236 | Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis. <i>New England Journal of Medicine</i> , 2007, 357, 2028-2039. | 27.0 | 806 |
| 237 | Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor \pm antagonists. <i>Arthritis and Rheumatism</i> , 2007, 56, 1125-1133. | 6.7 | 351 |
| 238 | Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor \pm antagonists. <i>Arthritis and Rheumatism</i> , 2007, 56, 4226-4227. | 6.7 | 76 |
| 239 | Racial/ethnic disparities in patient-reported nonsteroidal antiinflammatory drug (NSAID) risk awareness, patient-doctor NSAID risk communication, and NSAID risk behavior. <i>Arthritis and Rheumatism</i> , 2007, 57, 1539-1545. | 6.7 | 29 |
| 240 | Quality Indicators for the Care of Osteoarthritis in Vulnerable Elders. <i>Journal of the American Geriatrics Society</i> , 2007, 55, S383-91. | 2.6 | 31 |
| 241 | Prevention and treatment of glucocorticoid-induced osteoporosis. <i>Current Osteoporosis Reports</i> , 2007, 5, 14-21. | 3.6 | 19 |
| 242 | Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2007, 7, 101-112. | 5.7 | 24 |
| 243 | Epidemiology, risk factors, and lifestyle modifications for gout. <i>Arthritis Research and Therapy</i> , 2006, 8, S2. | 3.5 | 212 |
| 244 | Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 285-293. | 0.9 | 402 |
| 245 | Gout Medication Treatment Patterns and Adherence to Standards of Care From a Managed Care Perspective. <i>Mayo Clinic Proceedings</i> , 2006, 81, 925-934. | 3.0 | 265 |
| 246 | Pathophysiology, Clinical Presentation and Treatment of Gout. <i>Drugs</i> , 2006, 66, 1547-1563. | 10.9 | 46 |
| 247 | Treatment of rheumatoid arthritis. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 2451-2465. | 1.0 | 170 |
| 248 | New insights into gout epidemiology. <i>Current Opinion in Rheumatology</i> , 2006, 18, 199-203. | 4.3 | 52 |
| 249 | Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 11-18. | 1.9 | 9 |
| 250 | Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 710-718. | 1.9 | 59 |
| 251 | Unbalanced regulation of over-the-counter analgesics: the lesser of two evils?. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 410-411. | 1.9 | 5 |
| 252 | Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. <i>Osteoporosis International</i> , 2006, 17, 1268-1274. | 3.1 | 40 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 253 | Population-based assessment of adverse events associated with long-term glucocorticoid use. <i>Arthritis and Rheumatism</i> , 2006, 55, 420-426. | 6.7 | 448 |
| 254 | Osteoporosis in the home health care setting: A window of opportunity?. <i>Arthritis and Rheumatism</i> , 2006, 55, 971-975. | 6.7 | 11 |
| 255 | Comparison of Weekly Treatment of Postmenopausal Osteoporosis with Alendronate Versus Risedronate Over Two Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2631-2637. | 3.6 | 135 |
| 256 | Sex differences in gout epidemiology: evaluation and treatment. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1368-1372. | 0.9 | 128 |
| 257 | Improving the quality of clinical care for patients with osteoporosis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2006, 6, 641-645. | 1.4 | 0 |
| 258 | Smoking interacts with genetic risk factors in the development of rheumatoid arthritis among older Caucasian women. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1163-1167. | 0.9 | 72 |
| 259 | Trends in prevention of glucocorticoid-induced osteoporosis. <i>Journal of Rheumatology</i> , 2006, 33, 1651-7. | 2.0 | 43 |
| 260 | Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. <i>Arthritis and Rheumatism</i> , 2005, 52, 2485-2494. | 6.7 | 133 |
| 261 | Recent advances in the epidemiology of gout. <i>Current Rheumatology Reports</i> , 2005, 7, 235-241. | 4.7 | 18 |
| 262 | Gout treatment: What is evidence-based and how do we determine and promote optimized clinical care?. <i>Current Rheumatology Reports</i> , 2005, 7, 242-249. | 4.7 | 7 |
| 263 | The cost of glucocorticoid-associated adverse events in rheumatoid arthritis. <i>Rheumatology</i> , 2005, 44, 781-788. | 1.9 | 44 |
| 264 | Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 267-272. | 0.9 | 363 |
| 265 | Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). <i>Rheumatology</i> , 2005, 44, 1038-1042. | 1.9 | 138 |
| 266 | Developments in Glucocorticoid Therapy. <i>Rheumatic Disease Clinics of North America</i> , 2005, 31, 1-17. | 1.9 | 34 |
| 267 | Prevalence of osteoporosis and osteopenia among African Americans with early rheumatoid arthritis: the impact of ethnic-specific normative data. <i>Journal of the National Medical Association</i> , 2005, 97, 1155-60. | 0.8 | 40 |
| 268 | Racial disparities in the receipt of osteoporosis related healthcare among community-dwelling older women with arthritis and previous fracture. <i>Journal of Rheumatology</i> , 2005, 32, 870-5. | 2.0 | 31 |
| 269 | Evaluating and improving the quality of care in rheumatic disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2004, 4, 429-439. | 1.4 | 4 |
| 270 | Vitamin D intake is inversely associated with rheumatoid arthritis: Results from the Iowa Women's Health Study. <i>Arthritis and Rheumatism</i> , 2004, 50, 72-77. | 6.7 | 666 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 271 | Quality of care indicators for gout management. <i>Arthritis and Rheumatism</i> , 2004, 50, 937-943. | 6.7 | 130 |
| 272 | Measuring quality in arthritis care: Methods for developing the Arthritis Foundation's quality indicator set. <i>Arthritis and Rheumatism</i> , 2004, 51, 193-202. | 6.7 | 95 |
| 273 | Measuring quality in arthritis care: The Arthritis Foundation's quality indicator set for analgesics. <i>Arthritis and Rheumatism</i> , 2004, 51, 337-349. | 6.7 | 21 |
| 274 | Prevention of Glucocorticoid-induced Osteoporosis. <i>Southern Medical Journal</i> , 2004, 97, 555-558. | 0.7 | 19 |
| 275 | Estrogen and other female reproductive risk factors are not strongly associated with the development of rheumatoid arthritis in elderly women. <i>Seminars in Arthritis and Rheumatism</i> , 2003, 33, 72-82. | 3.4 | 106 |
| 276 | The effects of physician specialty and patient comorbidities on the use and discontinuation of coxibs. <i>Arthritis and Rheumatism</i> , 2003, 49, 293-299. | 6.7 | 26 |
| 277 | Glucocorticoid-induced osteoporosis. <i>Endocrinology and Metabolism Clinics of North America</i> , 2003, 32, 135-157. | 3.2 | 125 |
| 278 | Antioxidant Micronutrients and Risk of Rheumatoid Arthritis in a Cohort of Older Women. <i>American Journal of Epidemiology</i> , 2003, 157, 345-354. | 3.4 | 221 |
| 279 | Racial Disparities in Osteoporosis Prevention in a Managed Care Population. <i>Southern Medical Journal</i> , 2003, 96, 445-451. | 0.7 | 61 |
| 280 | Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women's Health Study. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 994-999. | 0.9 | 83 |
| 281 | Cigarette smoking and the risk of rheumatoid arthritis among postmenopausal women:. <i>American Journal of Medicine</i> , 2002, 112, 465-471. | 1.5 | 175 |
| 282 | Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: Results from the Iowa Women's Health Study. <i>Arthritis and Rheumatism</i> , 2002, 46, 83-91. | 6.7 | 147 |
| 283 | Glucocorticoid use in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2002, 4, 218-225. | 4.7 | 36 |
| 284 | Blood transfusion, alcohol use, and anthropometric risk factors for rheumatoid arthritis in older women. <i>Journal of Rheumatology</i> , 2002, 29, 246-54. | 2.0 | 97 |
| 285 | Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial. <i>Arthritis and Rheumatism</i> , 2001, 44, 202-211. | 6.7 | 485 |
| 286 | Resolved: Low-dose glucocorticoids are neither safe nor effective for the long-term treatment of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2001, 45, 468-471. | 6.7 | 16 |
| 287 | Preferences for Fractures and Other Glucocorticoid-Associated Adverse Effects among Rheumatoid Arthritis Patients. <i>Medical Decision Making</i> , 2001, 21, 122-132. | 2.4 | 29 |
| 288 | Practice Pattern Variation Among Internal Medicine Specialists in the Prevention of Glucocorticoid-Induced Osteoporosis. <i>Journal of Clinical Rheumatology</i> , 2000, 6, 117-122. | 0.9 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 289 | Rofecoxib. <i>Drugs</i> , 1999, 58, 506-507. | 10.9 | 0 |
| 290 | Nonsteroidal Anti-Inflammatory Drugs and Cognitive Function. <i>Drug Safety</i> , 1998, 19, 427-433. | 3.2 | 27 |
| 291 | Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. <i>New England Journal of Medicine</i> , 1998, 339, 292-299. | 27.0 | 1,192 |
| 292 | Arthritis health service utilization among the elderly: The role of urban-rural residence and other utilization factors. <i>Arthritis and Rheumatism</i> , 1998, 11, 177-185. | 6.7 | 20 |
| 293 | Low-dose corticosteroid therapy in rheumatoid arthritis: Balancing the evidence. <i>American Journal of Medicine</i> , 1997, 103, S31-S39. | 1.5 | 43 |
| 294 | Low-dose corticosteroids in rheumatoid arthritis. A meta-analysis of their moderate-term effectiveness. <i>Arthritis and Rheumatism</i> , 1996, 39, 1818-1825. | 6.7 | 81 |
| 295 | Nonsteroidal antiinflammatory drugs and cognitive decline in the elderly. <i>Journal of Rheumatology</i> , 1995, 22, 2142-7. | 2.0 | 40 |
| 296 | Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse events. <i>American Journal of Medicine</i> , 1994, 96, 115-123. | 1.5 | 470 |
| 297 | Nonsteroidal Anti-Inflammatory Drugs. <i>Spine</i> , 1994, 19, 1530-1534. | 2.0 | 13 |
| 298 | Understanding Physicians's™ Perceptions of Patient-Identified Barriers to Osteoporosis Medication Initiation: A Cognitive Mapping Approach. <i>Risk Management and Healthcare Policy</i> , 0, Volume 15, 1293-1302. | 2.5 | 0 |